<SEC-DOCUMENT>0001062993-18-004070.txt : 20181012
<SEC-HEADER>0001062993-18-004070.hdr.sgml : 20181012
<ACCEPTANCE-DATETIME>20181012170004
ACCESSION NUMBER:		0001062993-18-004070
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20181010
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181012
DATE AS OF CHANGE:		20181012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		181120725

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>October
10, 2018 </U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></U><BR></B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD align=center width="33%"><U><B>000-52138 </B></U></TD>
    <TD align=center width="33%"><U><B>20-2000871 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>156 Valleyview Road, Kelowna, BC Canada </B></U></TD>
    <TD align=center width="50%"><U><B>V1X 3M4 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424 </U></B></P>
<P align=center><B><U>N/A </U><BR></B>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b)) <BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))</P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;</P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.</P>
<P align=right>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 3.02 </B></TD>
    <TD align=left width="90%"><B>Unregistered Sales of Equity Securities
    </B></TD></TR></TABLE>
<P align=justify>On October 10, 2018, Lexaria received US$33,000<B> </B>from the
exercise of 330,000 options at the price of US$0.10 previously granted to a
third party who is neither an officer nor director of the Company. No
commissions or placement fees have been paid related to the funds received from
these options exercised. Proceeds will be used for general corporate purposes.
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center>- 2 - </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 7.01</B> </TD>
    <TD align=left width="90%"><B>Regulation FD Disclosure</B>
</TD></TR></TABLE>
<P align=justify>A copy of the news release announcing it has completed the
creation of four wholly-owned subsidiary companies is filed as exhibit 99.1 to
this current report and is hereby incorporated by reference.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 9.01</B> </TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits</B> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated October 10,
      2018 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: October 11, 2018 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_3></A>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Bioscience Creates and Brands Subsidiary Companies
</B></P>
<P align=justify>Kelowna, British Columbia &#150; October 10, 2018 &#150; Lexaria
Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug
delivery platform innovator, is pleased to announce it has completed the
creation of four wholly-owned subsidiary companies.</P>
<P align=justify>This new corporate structure more suitably reflects the
distinct customer bases and business applications for each subsidiary, thereby
allowing the Company to focus its future research and consider financing
structures and industry partnerships specifically optimized to each.</P>
<P align=justify>Each of the companies has a new website currently under
construction that is individualized for corporate purposes specific to that
company, but also clearly branded as part of the Lexaria group of companies. The
subsidiaries are each empowered with Lexaria&#146;s patented DehydraTECH<SUP>TM</SUP>
technology. </P><IMG src="exhibit99-1x3x1.jpg" border=0> <BR>
<P align=justify><B>Lexaria CanPharm Corp</B>., a Canadian company focused on
providing DehydraTECH technology and other enhancements to the global cannabis
industry. Lexaria CanPharm Corp. administers the Company&#146;s current
cannabis-related patent portfolio, which is one of the largest cannabis-focused
intellectual property suites in the world. Lexaria CanPharm is in active
discussions related to licensing its technology to companies located in Canada,
the USA, and Europe.</P><IMG src="exhibit99-1x3x2.jpg" border=0> <BR>
<P align=justify><B>Lexaria Nicotine Corp.</B>, a US company with a global
license to provide DehydraTECH technology to the global nicotine and tobacco
industries. Lexaria Nicotine Corp. administers the Company&#146;s nicotine-related
patent portfolio. Since mid 2017 the Company has had discussions with several
leading nicotine/tobacco companies around the world and will continue to work
towards a healthier consumer nicotine sector with potential industry partners
well-established in the industry. Lexaria Nicotine Corp. is focused on
reduced-risk nicotine solutions to help hundreds of million of existing smokers
lead healthier lives with lessened risk of cancer through avoidance of
combustible products. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A><IMG
src="exhibit99-1x4x1.jpg" border=0> <BR>
<P align=justify><B>Lexaria Hemp Corp.</B>, a US company globally licensed to
provide DehydraTECH to the rapidly growing hemp-based foods and supplements
industries. Lexaria Hemp Corp. is currently involved in discussions with a
number of companies regarding the utilization of its technology in CBD-from-hemp
products for the Canadian and US markets following recent announcements of
regulatory advancement in both countries. Discussions with companies in other
global markets are also underway with reportable progress expected soon. Lexaria
Hemp Corp. will also soon announce the creation of a new wholly-owned brand that
will be introducing a new category-killer product at the upcoming MJBiz
conference in Las Vegas on November 14-16, 2018 where Lexaria will be exhibiting
at booth 3227. Lexaria will set new standards that exceed consumers expectations
and continue to advance the industry as we have done so since 2014.</P><IMG
src="exhibit99-1x4x2.jpg" border=0> <BR>
<P align=justify><B>Lexaria Pharmaceutical Corp</B>., a US company globally
empowered to license DehydraTECH to the large and diverse pharmaceutical
sectors, including pain relief, vitamins, PDE5 inhibitors, hormone treatments,
central nervous system conditions, and more. Lexaria Pharma will manage the
broadest set of intellectual property of all the Lexaria family of companies and
is in the R&amp;D and product development phase.</P>
<P align=justify>Lexaria also announces it will utilize wholly-owned Poviva Tea
Corp., to advance the existing ViPova Tea and Coffee consumer brands. Recent
signs of legislative easing in the US support the possibility of renewed
distribution possibilities for these brands.</P>
<P align=justify>Separately, Lexaria has received US$33,000<B> </B>from the
exercise of 330,000 options at the price of US$0.10 previously granted to a
third party who is neither an officer nor director of the Company. No
commissions or placement fees have been paid related to the funds received from
these options exercised. Proceeds will be used for general corporate
purposes.</P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has eight patents granted in the USA and in </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=justify>Australia and has filed over 50 patent applications worldwide
across ten patent families. Lexaria&#146;s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <U>www.lexariabioscience.com</U>&nbsp;&nbsp;</P><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp;<IMG src="exhibit99-1x5x1.jpg" border=0></TD>
    <TD vAlign=bottom align=left width="90%">For regular updates, connect with
      Lexaria on Twitter <U>https://twitter.com/lexariacorp</U> </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;<IMG src="exhibit99-1x5x2.jpg" border=0></TD>
    <TD vAlign=bottom align=left width="90%">and on Facebook
      <U>https://www.facebook.com/lexariabioscience/</U>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>FOR FURTHER INFORMATION PLEASE CONTACT: </TD></TR>
  <TR vAlign=top>
    <TD align=left>Lexaria Bioscience Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>Alex Blanchard, Communications Manager </TD></TR>
  <TR vAlign=top>
    <TD align=left>(778) 796-1897 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Or </TD></TR>
  <TR vAlign=top>
    <TD align=left>NetworkNewsWire (NNW) </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>www.NetworkNewsWire.com</U> </TD></TR></TABLE>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. Scientific R&amp;D is often
unpredictable and unanticipated results could emerge from any study and have a
material impact as can any results that cannot be reproduced in subsequent
testing. There is no assurance that any planned corporate activity, scientific
study, R&amp;D, business venture, or initiative will be pursued, or if pursued,
will be successful. There is no assurance that any of Lexaria&#146;s postulated uses,
benefits, or advantages for the patented and patent-pending technology will in
fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). TurboCBD<SUP>TM</SUP>,
DehydraTECH<SUP>TM</SUP> technology and ViPova<SUP>TM</SUP> products are not
intended to diagnose, treat, cure or prevent any disease. </P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit99-1x3x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x3x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" != +D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T"BBB@ HH
MHH **2B@!:2B@L%&20!ZF@!:*I3:@J*3&A?]!5M6W*&'<9J8SC+8'H.HHHJ@
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJE\FG6,EP_)485?[Q["K
M=<QXV<BVM8QT+LWY#_Z]5%7=BHJ[-31]8AU2+Y?DF4?/'Z>X]16E7F5C=R6-
MW'<1'#(?S'<5Z3;3I=6\<\?W)%##-5./*5.-M4+-,D$322L%1>I-<_<ZFUU+
MQ\L0^Z/7ZU6\2ZD9+S[+&W[N+[V.[?\ UJSX9:XZ_,U9';A\.E'FEU-V&7=Q
MUK>0;44>@Q7-Z0IN+M5[+\Q^E=+48:+2;.?$I1E86BBBNLY@HHHH **** "B
MBB@ HHHH **** "BBB@ HHI* %KF?&R9MK63T<K^8_\ K5TN<UG:_:&\TF9%
M7+J-Z?4?Y-.+L[C3LSSRNV\.7:Q^&S+(?EM]^?H.?ZUQ1%=%IQ*>#=0/K(1^
M>T5O/5&LG=&"TIED:1C\SL6/U-3V[,SJB@L2< #DFH+6VGNI1%;QM(Y[*.GU
M]*[30M!&G_O[DJ\_;'1/_KUG5@CM6(4(ZEO1K V=KF0#SGY;V]JT**S/$MW/
M8Z#=7-L^R9 NUL X^8#O]:S2MHCSI2<G=FI16!X-U"ZU+1FGO)?-E$S+NP!Q
M@>GUK==UC0N[!549+$X %-JSL2.HK*M_$FCW5R+>&^C,A. "" ?H2,&I;_6]
M.TV=8;VY$+L-P#*W(^N*+,#0HK-O=>TO3Y%CNKQ$=E#@8)R#T/ I;[7--TX(
M;NZ6,R#<JD$L1ZX S18#1HJEI^JV.IJS65RDVW[P'!'U!YJO)XDT>.6:*2^C
M5X20ZD$8(.".G)SZ46 U*6L*^U6+4M%FFTC4X('1E!FE.P)ST.1QGZ5/I5V;
M;0DN-2U""<KNWW"/E#R>AX^E%@-:BLFT\2Z/>3"&&^0R'@!@5S],BM6E:P"T
M444 %4-:MGNM+FCCSO W+@]<=JOT4 >:PW$]NVZ&62-O]EB*Z#2O%!4B+4>1
MVE _F!4^M^'3<2-<V6 [<O&> Q]1[URLD;QN4=2K#J",&F1JB]KFGFTNC/&
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I"C-344#"BBB@!**6B@!*6BB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>exhibit99-1x3x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x3x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !8 +H# 2(  A$! Q$!_\0
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MC*L&'3@UC&\>X)+'"G^$=*T-.4+ V.A;^@K&%=3ERHJ4''<MT4E+6Y 4444
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M2E"PH0G\4A'RK_\ 7KJY/#=I/?RW5PSR>8V[R\X'^-:\44<,2QQ(J(HP%48
MK*4U:R*C7<%[I#86<5A:K!$.%ZD]2?6K%%+61@VV[LP-"\2'6-2N;3[+Y7D
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>exhibit99-1x4x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x4x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !; +D# 2(  A$! Q$!_\0
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M;OQ+XCTZ-;F_TR".W9MO<'/I]XXZ>E=C;3+<VT4Z9VRH'7/H1FDTT!+1112
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M*[%HHV.612?<4,1'&S 8"C.!6*IN]VSI]NDK11SPN9-&@,._S;A^=I.5C_\
MKU!J=W=&WTZY+XE^9@0,#.?\,4EM:2ZC=DG.UCEW/:MK5=-%Y9K'$ KQ?ZL=
MOI5P;:'+EC)7W%MK*SN#!?K J2E0X*Y')'?'6M&H+.'[/:10DY** ?K4]6<S
MW*&J!R;01D*_G#!(R!P::R7*WEJ9Y8W7><!4(_A/O5V2))2A<9*-N7V-*T:N
MR,PY0Y7VXQ4.-V6IV5BG>B4WMJ(757VORRY':K,"SJI\^1'/;:NW^M$UM%.R
MF0$E<X(8C&?I2Q0)#G9NYZ[G+?SII6=Q-IQ2,XDVT\EV%)42LDF!SCC!_/\
MG3K"-TOBTO\ K)(=[>V6Z?ATK12-4W;1C<=Q^M'E)YOFX^?;MS[5/(/G*<GV
MC^T9?L_E_P"J3._/JWI4UK;O&TDLS*TLA&=HP !T J81J)#(!\[  GV'_P"N
MG521+8M%%%42%%%% !1110 4444 %%%% !2$ @@C(/:EHH :B+&NU%"CT Q3
JJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exhibit99-1x4x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x4x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" !5 +P# 2(  A$! Q$!_\0
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M+T7PY'8.)[EA-,!\HQ\J'U]S6[38I!+$DB@@.H8 ]>:?6#;;U'*3EJRIJO\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>exhibit99-1x5x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x5x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  L #0# 2(  A$! Q$!_\0
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<5$B?05)45<4YJT=#2A@(TY<TG<**6BN0]$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>exhibit99-1x5x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit99-1x5x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  M #H# 2(  A$! Q$!_\0
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KR\\GZUU:11QYV1JN?[HQ3ZJ59M60E32W$50JA5  '0"C(]_RI:*P-#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
